Dramatic response to combination erlotinib and crizotinib in a patient with advanced, EGFR-mutant lung cancer harboring de Novo MET amplification

Journal of Thoracic Oncology

Volumn 11, Issue 7, 2016, Pages e83-e85

  Gainor, Justin F ^a   Niederst, Matthew J ^a   Lennerz, Jochen K ^a   Dagogo Jack, Ibiayi ^a   Stevens, Sara ^a   Shaw, Alice T ^a   Sequist, Lecia V ^a   Engelman, Jeffrey A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MET PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHROMOSOME 7; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DRUG TOLERABILITY; DYSPNEA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG BIOPSY; MALE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; THORACOCENTESIS; THORAX PAIN; TREATMENT RESPONSE; FEMALE; GENETICS; LUNG TUMOR; MUTATION; PATHOLOGY; PROGNOSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ERLOTINIB HYDROCHLORIDE; FEMALE; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84978245406     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.02.021     Document Type: Article

References (7)

1. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6:942-946.
2. Ou S, Govindan R, Eaton K, et al. Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2012;30(suppl): 2610.
3. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3, 75ra26.
4. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-1043.
5. Planchard D, Loriot Y, André F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26:2073-2078.
6. Bean J, Brennan C, Shih JY, et al. METamplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007;104:20932-20937.
7. Scheffler M, Merkelbach-Bruse S, Bos M, et al. Spatial tumor heterogeneity in lung cancer with acquired epidermal growth factor receptor-tyrosine kinase inhibitor resistance: targeting high-level MET-amplification and EGFR T790M mutation occurring at different sites in the same patient. J Thorac Oncol. 2015;10:e40-e43.